Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	regulation of synapse assembly	GRIN1 OGT ADGRL2 CBLN1 CBLN2	2.53e-05	202	36	5	GO:0051963
GeneOntologyBiologicalProcess	T cell differentiation	NCOR1 DUSP10 PBRM1 PIK3R6 AP3B1 LEP	4.72e-05	382	36	6	GO:0030217
GeneOntologyBiologicalProcess	cell-cell adhesion	PKHD1 COL14A1 FAT4 DUSP10 PBRM1 PIK3R6 AP3B1 CBLN1 LEP	7.31e-05	1077	36	9	GO:0098609
GeneOntologyBiologicalProcess	cellular response to nutrient levels	CD68 DEPDC5 OGT MDM2 LEP	8.70e-05	262	36	5	GO:0031669
GeneOntologyBiologicalProcess	positive regulation of T cell differentiation	DUSP10 PBRM1 PIK3R6 AP3B1	1.13e-04	144	36	4	GO:0045582
GeneOntologyBiologicalProcess	cellular response to nutrient	OGT MDM2 LEP	1.20e-04	55	36	3	GO:0031670
GeneOntologyBiologicalProcess	positive regulation of T cell activation	DUSP10 PBRM1 PIK3R6 AP3B1 LEP	1.40e-04	290	36	5	GO:0050870
GeneOntologyBiologicalProcess	regulation of TOR signaling	PKHD1 DEPDC5 OGT LEP	1.61e-04	158	36	4	GO:0032006
GeneOntologyBiologicalProcess	positive regulation of lymphocyte differentiation	DUSP10 PBRM1 PIK3R6 AP3B1	1.78e-04	162	36	4	GO:0045621
GeneOntologyBiologicalProcess	synapse assembly	GRIN1 OGT ADGRL2 CBLN1 CBLN2	1.85e-04	308	36	5	GO:0007416
GeneOntologyBiologicalProcess	regulation of cell junction assembly	GRIN1 OGT ADGRL2 CBLN1 CBLN2	1.88e-04	309	36	5	GO:1901888
GeneOntologyBiologicalProcess	positive regulation of leukocyte cell-cell adhesion	DUSP10 PBRM1 PIK3R6 AP3B1 LEP	2.12e-04	317	36	5	GO:1903039
GeneOntologyBiologicalProcess	TOR signaling	PKHD1 DEPDC5 OGT LEP	2.71e-04	181	36	4	GO:0031929
GeneOntologyBiologicalProcess	lymphocyte differentiation	NCOR1 DUSP10 PBRM1 PIK3R6 AP3B1 LEP	3.03e-04	537	36	6	GO:0030098
GeneOntologyBiologicalProcess	magnesium ion homeostasis	CNNM4 XK	3.96e-04	17	36	2	GO:0010960
GeneOntologyBiologicalProcess	cell junction assembly	GRIN1 OGT PATJ ADGRL2 CBLN1 CBLN2	4.13e-04	569	36	6	GO:0034329
GeneOntologyBiologicalProcess	positive regulation of synapse assembly	ADGRL2 CBLN1 CBLN2	4.52e-04	86	36	3	GO:0051965
GeneOntologyBiologicalProcess	positive regulation of cell adhesion	DUSP10 PBRM1 PIK3R6 AP3B1 LEP CARMIL1	4.53e-04	579	36	6	GO:0045785
GeneOntologyBiologicalProcess	regulation of cell-cell adhesion	PKHD1 DUSP10 PBRM1 PIK3R6 AP3B1 LEP	4.57e-04	580	36	6	GO:0022407
GeneOntologyBiologicalProcess	positive regulation of reactive oxygen species metabolic process	GRIN1 OGT LEP	5.00e-04	89	36	3	GO:2000379
GeneOntologyBiologicalProcess	positive regulation of lymphocyte activation	DUSP10 PBRM1 PIK3R6 AP3B1 LEP	5.17e-04	385	36	5	GO:0051251
GeneOntologyBiologicalProcess	regulation of synapse organization	GRIN1 OGT ADGRL2 CBLN1 CBLN2	5.29e-04	387	36	5	GO:0050807
GeneOntologyBiologicalProcess	positive regulation of cell-cell adhesion	DUSP10 PBRM1 PIK3R6 AP3B1 LEP	5.42e-04	389	36	5	GO:0022409
GeneOntologyBiologicalProcess	regulation of synapse structure or activity	GRIN1 OGT ADGRL2 CBLN1 CBLN2	5.81e-04	395	36	5	GO:0050803
GeneOntologyBiologicalProcess	regulation of T cell differentiation	DUSP10 PBRM1 PIK3R6 AP3B1	6.28e-04	226	36	4	GO:0045580
GeneOntologyBiologicalProcess	cellular component maintenance	GRIN1 CBLN1 CBLN2	7.24e-04	101	36	3	GO:0043954
GeneOntologyBiologicalProcess	mononuclear cell differentiation	NCOR1 DUSP10 PBRM1 PIK3R6 AP3B1 LEP	7.68e-04	640	36	6	GO:1903131
GeneOntologyBiologicalProcess	positive regulation of leukocyte activation	DUSP10 PBRM1 PIK3R6 AP3B1 LEP	7.91e-04	423	36	5	GO:0002696
GeneOntologyBiologicalProcess	fibroblast activation	MDM2 LEP	7.98e-04	24	36	2	GO:0072537
GeneOntologyBiologicalProcess	positive regulation of leukocyte differentiation	DUSP10 PBRM1 PIK3R6 AP3B1	8.11e-04	242	36	4	GO:1902107
GeneOntologyBiologicalProcess	positive regulation of hemopoiesis	DUSP10 PBRM1 PIK3R6 AP3B1	8.11e-04	242	36	4	GO:1903708
GeneOntologyCellularComponent	synaptic cleft	GRIN1 CBLN1 CBLN2	2.91e-05	33	38	3	GO:0043083
GeneOntologyCellularComponent	dendritic branch	GRIN1 AKAP9	6.72e-05	7	38	2	GO:0044307
Domain	C1Q	CBLN1 CBLN2	1.92e-03	32	38	2	SM00110
Domain	C1q	CBLN1 CBLN2	1.92e-03	32	38	2	PF00386
Domain	C1q_dom	CBLN1 CBLN2	2.17e-03	34	38	2	IPR001073
Domain	C1Q	CBLN1 CBLN2	2.17e-03	34	38	2	PS50871
Domain	-	CBLN1 CBLN2	4.64e-03	50	38	2	2.60.120.40
Domain	Laminin_G	COL14A1 FAT4	6.20e-03	58	38	2	IPR001791
Domain	Tumour_necrosis_fac-like_dom	CBLN1 CBLN2	6.20e-03	58	38	2	IPR008983
Domain	-	ZER1 HEATR1 AP3B1	1.03e-02	222	38	3	1.25.10.10
Pubmed	NMDA and AMPA glutamate receptor subtypes in the thoracic spinal cord in lean and obese-diabetic ob/ob mice.	GRIN1 LEP	1.16e-06	2	38	2	10592285
Pubmed	Yotiao, a novel protein of neuromuscular junction and brain that interacts with specific splice variants of NMDA receptor subunit NR1.	GRIN1 AKAP9	1.16e-06	2	38	2	9482789
Pubmed	Cerebellin-2 regulates a serotonergic dorsal raphe circuit that controls compulsive behaviors.	CBLN1 CBLN2	1.16e-06	2	38	2	34158618
Pubmed	Parcellation of cerebellins 1, 2, and 4 among different subpopulations of dorsal horn neurons in mouse spinal cord.	CBLN1 CBLN2	3.48e-06	3	38	2	23853053
Pubmed	Genetic Ablation of All Cerebellins Reveals Synapse Organizer Functions in Multiple Regions Throughout the Brain.	CBLN1 CBLN2	3.48e-06	3	38	2	29691328
Pubmed	Cerebellins are differentially expressed in selective subsets of neurons throughout the brain.	CBLN1 CBLN2	3.48e-06	3	38	2	28714144
Pubmed	Comparison of Cbln1 and Cbln2 functions using transgenic and knockout mice.	CBLN1 CBLN2	3.48e-06	3	38	2	22117778
Pubmed	Characterization of a transneuronal cytokine family Cbln--regulation of secretion by heteromeric assembly.	CBLN1 CBLN2	6.96e-06	4	38	2	17331201
Pubmed	Distinct expression of Cbln family mRNAs in developing and adult mouse brains.	CBLN1 CBLN2	6.96e-06	4	38	2	16930405
Pubmed	Cbln family proteins promote synapse formation by regulating distinct neurexin signaling pathways in various brain regions.	CBLN1 CBLN2	6.96e-06	4	38	2	21410790
Pubmed	Glutamate receptor δ1 induces preferentially inhibitory presynaptic differentiation of cortical neurons by interacting with neurexins through cerebellin precursor protein subtypes.	CBLN1 CBLN2	6.96e-06	4	38	2	22191730
Pubmed	Cbln1 is essential for interaction-dependent secretion of Cbln3.	CBLN1 CBLN2	6.96e-06	4	38	2	17030622
Pubmed	Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.	NCOR1 LEP	6.96e-06	4	38	2	26120082
Pubmed	A Human Tyrosine Phosphatase Interactome Mapped by Proteomic Profiling.	ARHGAP1 CNNM4 DUSP10 HEATR1 OGT ADGRL2 AP3B1 NT5DC2	8.53e-06	974	38	8	28675297
Pubmed	Distinct neurexin-cerebellin complexes control AMPA- and NMDA-receptor responses in a circuit-dependent manner.	CBLN1 CBLN2	1.16e-05	5	38	2	36205393
Pubmed	p21-activated kinase 4 suppresses fatty acid β-oxidation and ketogenesis by phosphorylating NCoR1.	NCOR1 LEP	1.16e-05	5	38	2	37591884
Pubmed	JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells.	NCOR1 MDM2	1.74e-05	6	38	2	28549433
Pubmed	Distinct expression of C1q-like family mRNAs in mouse brain and biochemical characterization of their encoded proteins.	CBLN1 CBLN2	1.74e-05	6	38	2	20525073
Pubmed	Cbln1 Directs Axon Targeting by Corticospinal Neurons Specifically toward Thoraco-Lumbar Spinal Cord.	CBLN1 CBLN2	2.43e-05	7	38	2	36823038
Pubmed	Glycosylation of Cblns attenuates their receptor binding.	CBLN1 CBLN2	2.43e-05	7	38	2	29782851
Pubmed	SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.	NCOR1 HEATR1 OGT PATJ AP3B1 ERCC6L	2.71e-05	549	38	6	38280479
Pubmed	Differential interactions of cerebellin precursor protein (Cbln) subtypes and neurexin variants for synapse formation of cortical neurons.	CBLN1 CBLN2	4.16e-05	9	38	2	21356198
Pubmed	Disentangling the detrimental effects of local from systemic adipose tissue dysfunction on articular cartilage in the knee.	CD68 LEP	6.35e-05	11	38	2	39103079
Pubmed	CIPP, a novel multivalent PDZ domain protein, selectively interacts with Kir4.0 family members, NMDA receptor subunits, neurexins, and neuroligins.	GRIN1 PATJ	6.35e-05	11	38	2	9647694
Pubmed	Genomic structure and mapping of precerebellin and a precerebellin-related gene.	CBLN1 CBLN2	9.00e-05	13	38	2	7877445
Pubmed	Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS.	CCNT2 HEATR1 AKAP9 PATJ VPS13B	1.03e-04	432	38	5	23455922
Pubmed	Pigmentation-related genes and their implication in malignant melanoma susceptibility.	AP3B1 VPS13B	1.05e-04	14	38	2	19320733
Pubmed	Mutations in mice that influence natural killer (NK) cell activity.	AP3B1 LEP	1.05e-04	14	38	2	6971254
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	ARHGAP1 PATJ ADGRL2 AP3B1 ERCC6L CARMIL1	1.10e-04	708	38	6	39231216
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	ARHGAP1 CNNM4 NCOR1 DUSP10 AKAP9 ADGRL2 AP3B1	1.24e-04	1049	38	7	27880917
Pubmed	Olfactory receptors and signalling elements in the Grueneberg ganglion.	OR4D1 OR7A17	1.56e-04	17	38	2	16805845
Pubmed	Polη O-GlcNAcylation governs genome integrity during translesion DNA synthesis.	OGT MDM2	1.56e-04	17	38	2	29208956
Pubmed	Mammalian Otolin: a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein Otoconin-90 and Cerebellin-1.	CBLN1 CBLN2	1.56e-04	17	38	2	20856818
Pubmed	Comprehensive interactome profiling of the human Hsp70 network highlights functional differentiation of J domains.	ARHGAP1 COL14A1 HEATR1 AKAP9 ADGRL2 AP3B1 NT5DC2 VPS13B	1.70e-04	1487	38	8	33957083
Pubmed	Genome-wide association analysis demonstrates the highly polygenic character of age-related hearing impairment.	DEPDC5 SEPTIN14	1.76e-04	18	38	2	24939585
Pubmed	Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4.	CNNM4 PBRM1 NT5DC2	1.92e-04	102	38	3	21926972
Pubmed	Fibril treatment changes protein interactions of tau and α-synuclein in human neurons.	ARHGAP1 HEATR1 PBRM1 AP3B1 NT5DC2	2.01e-04	498	38	5	36634849
Pubmed	The Schizophrenia Susceptibility Gene OPCML Regulates Spine Maturation and Cognitive Behaviors through Eph-Cofilin Signaling.	GRIN1 OPCML	2.41e-04	21	38	2	31577955
Pubmed	Mapping of Cbln1-like immunoreactivity in adult and developing mouse brain and its localization to the endolysosomal compartment of neurons.	CBLN1 CBLN2	2.90e-04	23	38	2	18001291
Pubmed	Specific repertoire of olfactory receptor genes in the male germ cells of several mammalian species.	OR4D1 OR7A17	3.16e-04	24	38	2	9119360
Pubmed	Development and application of a DNA microarray-based yeast two-hybrid system.	DUSP10 ERCC6L OPCML	4.96e-04	141	38	3	23275563
Pubmed	Systematic mapping of genetic interactions for de novo fatty acid synthesis identifies C12orf49 as a regulator of lipid metabolism.	OR4D1 ARHGAP1 CCNT2 DEPDC5 HEATR1 OGT PBRM1	5.18e-04	1327	38	7	32694731
Pubmed	Developmental trajectories of thalamic progenitors revealed by single-cell transcriptome profiling and Shh perturbation.	CBLN1 CBLN2	5.30e-04	31	38	2	36476860
Pubmed	A Large-scale genetic association study of esophageal adenocarcinoma risk.	AKAP9 MDM2 LEP MUTYH	5.74e-04	351	38	4	20453000
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	NCOR1 FAT4 PBRM1 AP3B1 ERCC6L	6.22e-04	638	38	5	31182584
Pubmed	The variant Polycomb Repressor Complex 1 component PCGF1 interacts with a pluripotency sub-network that includes DPPA4, a regulator of embryogenesis.	PBRM1 AKAP9 NT5DC2 MUTYH	9.00e-04	396	38	4	26687479
Cytoband	6p22.2	SLC17A4 CARMIL1	6.96e-05	15	38	2	6p22.2
Coexpression	GSE7509_UNSTIM_VS_FCGRIIB_STIM_MONOCYTE_DN	CCNT2 NCOR1 ZER1 DEPDC5 OGT	4.07e-06	166	38	5	M6826
CoexpressionAtlas	DevelopingKidney_e15.5_anlage of loop of Henle_emap-31283_top-relative-expression-ranked_1000	PKHD1 CCNT2 NCOR1 COL14A1 OGT AKAP9 PATJ ABCA13 VPS13B	6.69e-06	795	37	9	gudmap_developingKidney_e15.5_anlage of loop of Henle_1000
CoexpressionAtlas	DevelopingKidney_e15.5_anlage of loop of Henle_emap-31283_k-means-cluster#3_top-relative-expression-ranked_1000	CCNT2 NCOR1 OGT AKAP9 ABCA13 VPS13B	4.53e-05	379	37	6	gudmap_developingKidney_e15.5_1000_k3
CoexpressionAtlas	DevelopingLowerUrinaryTract_e14.5_ bladder_emap-30872_top-relative-expression-ranked_1000	NCOR1 COL14A1 FAT4 XK HEATR1 OGT AP3B1 ERCC6L	6.31e-05	811	37	8	gudmap_developingLowerUrinaryTract_e14.5_ bladder_1000
CoexpressionAtlas	dev gonad_e11.5_F_SupCellPrec_Sry_k-means-cluster#1_top-relative-expression-ranked_1000	FAT4 AKAP9 PATJ ADGRL2 AP3B1	9.66e-05	268	37	5	gudmap_dev gonad_e11.5_F_SupCellPrec_Sry_k1_1000
CoexpressionAtlas	DevelopingKidney_e15.5_anlage of loop of Henle_emap-31283_top-relative-expression-ranked_200	PKHD1 AKAP9 PATJ ABCA13	1.50e-04	155	37	4	gudmap_developingKidney_e15.5_anlage of loop of Henle_200
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_3\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 COL14A1 ABCA13 CBLN2	6.64e-06	143	38	4	7a7a9829ba63468c9745904d9e993590051207ab
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Vip-Vip_Chat_Htr1f\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	FAT4 DUSP10 NT5DC2 CBLN2	1.34e-05	171	38	4	f9ae7964a3740f559431125c17c660549798cccc
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 COL14A1 PATJ ABCA13	1.87e-05	186	38	4	f0c8de4f6ae9047b9108a47a2af8c5f42bc103b0
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 COL14A1 PATJ ADGRL2	1.91e-05	187	38	4	77886f99c229610abd28c4c370d2c7d1536c9782
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	COL14A1 CBLN1 ABCA13 CBLN2	1.91e-05	187	38	4	9225caf66e06ebe57e90d677122acb6498607f36
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	PKHD1 COL14A1 ABCA13 CBLN2	2.16e-05	193	38	4	0f2167eef8203a5659c8c72e4e77646003d64797
ToppCell	Smart-start-Cell-Wel_seq-Neoplastic-Stem-like-NPC-like-NPC-like_neural-F\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	OR4D1 CNNM4 ZER1 MUTYH	2.16e-05	193	38	4	088c8b1e968f5356502347eaabdc6b1b1d4befd0
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	COL14A1 FAT4 ADGRL2 CBLN2	2.25e-05	195	38	4	1cdf5f296029ae424d9dba42e86a6d111e4896e6
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature1_(0)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	COL14A1 FAT4 ADGRL2 CARMIL1	2.34e-05	197	38	4	11a4c417f035e554431a8f03be13b5eefa3530c0
ToppCell	kidney_cells-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	SLC17A4 PKHD1 DEPDC5 AKAP9	2.44e-05	199	38	4	174f6013af6eafa577f84205a62927f2b367fda3
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW08-Neuronal-Intermediate\|GW08 / Sample Type, Dataset, Time_group, and Cell type.	XK IQCH PATJ CBLN2	2.48e-05	200	38	4	401d50fa394fa863fa7836344110ae5c7af3250a
Drug	Dicloxacillin sodium salt [13412-64-1]; Up 200; 8.2uM; MCF7; HT_HG-U133A	ARHGAP1 ZER1 OGT MDM2 VPS13B	1.43e-05	187	38	5	5012_UP
Drug	Xylazine [7361-61-7]; Up 200; 18.2uM; HL60; HT_HG-U133A	ZER1 FAT4 DEPDC5 MDM2 CARMIL1	1.75e-05	195	38	5	2132_UP
Drug	Pregnenolone [145-13-1]; Down 200; 12.6uM; MCF7; HT_HG-U133A	CNNM4 ZER1 PATJ MDM2 VPS13B	1.79e-05	196	38	5	2856_DN
Drug	Clemastine fumarate [14976-57-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A	CNNM4 CCNT2 NCOR1 ZER1 PATJ	1.79e-05	196	38	5	7485_DN
Drug	Oxantel pamoate [68813-55-8]; Up 200; 6.6uM; HL60; HT_HG-U133A	ARHGAP1 ZER1 AKAP9 MDM2 AP3B1	1.93e-05	199	38	5	1277_UP
Drug	Diflunisal [22494-42-4]; Down 200; 16uM; MCF7; HT_HG-U133A	CCNT2 ZER1 DUSP10 PATJ MDM2	1.97e-05	200	38	5	1490_DN
Drug	AC1L3OOT	NCOR1 AP3B1 LEP	7.96e-05	50	38	3	CID000119371
Drug	Bisacodyl [603-50-9]; Up 200; 11uM; MCF7; HT_HG-U133A	CCNT2 DUSP10 OGT AKAP9	1.86e-04	171	38	4	3297_UP
Drug	17-AAG; Up 200; 1uM; HL60; HT_HG-U133A	CNNM4 ZER1 GRIN1 VPS13B	2.12e-04	177	38	4	2678_UP
Drug	pararosaniline base; Up 200; 10uM; MCF7; HT_HG-U133A_EA	CCNT2 COL14A1 OGT PATJ	2.12e-04	177	38	4	893_UP
Drug	17-AAG; Up 200; 1uM; HL60; HT_HG-U133A	ZER1 COL14A1 MDM2 LEP	2.17e-04	178	38	4	2685_UP
Drug	Fendiline hydrochloride [13636-18-5]; Up 200; 11.4uM; MCF7; HT_HG-U133A	FAT4 DEPDC5 DUSP10 GRIN1	2.41e-04	183	38	4	3190_UP
Drug	LY 294002; Up 200; 10uM; PC3; HT_HG-U133A	COL14A1 AKAP9 ADGRL2 OPCML	2.56e-04	186	38	4	4463_UP
Drug	Ethopropazine hydrochloride [1094-08-2]; Down 200; 11.4uM; MCF7; HT_HG-U133A	NCOR1 MDM2 AP3B1 CARMIL1	2.78e-04	190	38	4	5296_DN
Drug	17-AAG; Down 200; 1uM; PC3; HT_HG-U133A	ARHGAP1 ZER1 DUSP10 PATJ	2.89e-04	192	38	4	4450_DN
Drug	ionomycin calcium salt; Down 200; 2uM; MCF7; HT_HG-U133A_EA	CCNT2 AKAP9 MDM2 ADGRL2	2.95e-04	193	38	4	979_DN
Drug	Fluorometholone [426-13-1]; Up 200; 10.6uM; HL60; HT_HG-U133A	CCNT2 ZER1 GRIN1 MDM2	2.95e-04	193	38	4	2509_UP
Drug	Metanephrine hydrochloride DL [881-95-8]; Down 200; 17.2uM; PC3; HT_HG-U133A	ZER1 PATJ MDM2 MUTYH	2.95e-04	193	38	4	6734_DN
Drug	Haloperidol [52-86-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A	ZER1 FAT4 DEPDC5 DUSP10	2.95e-04	193	38	4	5273_UP
Drug	GSK-3 Inhibitor IX; Up 200; 0.5uM; MCF7; HT_HG-U133A	NCOR1 DEPDC5 PATJ AP3B1	3.01e-04	194	38	4	7044_UP
Drug	Acemetacin [53164-05-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A	ZER1 GRIN1 PATJ MDM2	3.01e-04	194	38	4	7442_UP
Drug	Meclozine dihydrochloride [1104-22-9]; Up 200; 8.6uM; MCF7; HT_HG-U133A	ZER1 DEPDC5 DUSP10 OGT	3.01e-04	194	38	4	3285_UP
Drug	Scoulerine [6451-73-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	CCNT2 DUSP10 MDM2 VPS13B	3.01e-04	194	38	4	2891_DN
Drug	Benfotiamine [22457-89-2]; Up 200; 8.6uM; PC3; HT_HG-U133A	SLC17A4 COL14A1 DEPDC5 MDM2	3.07e-04	195	38	4	4312_UP
Drug	Guanfacine hydrochloride [29110-48-3]; Up 200; 14.2uM; MCF7; HT_HG-U133A	ZER1 FAT4 OR7A17 MDM2	3.07e-04	195	38	4	5256_UP
Drug	2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A_EA	ARHGAP1 DUSP10 OGT MDM2	3.07e-04	195	38	4	989_DN
Drug	S-(+)-ibuprofen [51146-56-6]; Down 200; 19.4uM; HL60; HT_HG-U133A	ARHGAP1 CCNT2 ZER1 MDM2	3.13e-04	196	38	4	3094_DN
Drug	Piperine [94-62-2]; Up 200; 14uM; MCF7; HT_HG-U133A	CCNT2 ZER1 DEPDC5 MDM2	3.13e-04	196	38	4	3263_UP
Drug	Benzonatate [104-31-4]; Down 200; 6.6uM; MCF7; HT_HG-U133A	ZER1 XK MDM2 VPS13B	3.13e-04	196	38	4	5435_DN
Drug	Ethaverine hydrochloride [985-13-7]; Up 200; 9.2uM; MCF7; HT_HG-U133A	ARHGAP1 FAT4 OGT AKAP9	3.13e-04	196	38	4	3375_UP
Drug	Bucladesine sodium salt [16980-89-5]; Up 200; 7.8uM; HL60; HT_HG-U133A	SLC17A4 COL14A1 MDM2 LEP	3.13e-04	196	38	4	2741_UP
Drug	Clofazimine [2030-63-9]; Up 200; 8.4uM; MCF7; HT_HG-U133A	SLC17A4 DEPDC5 PATJ OPCML	3.13e-04	196	38	4	5642_UP
Drug	Diphenylpyraline hydrochloride [132-18-3]; Up 200; 12.6uM; MCF7; HT_HG-U133A	SLC17A4 COL14A1 DEPDC5 OPCML	3.13e-04	196	38	4	6061_UP
Drug	Aminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; MCF7; HT_HG-U133A	NCOR1 ZER1 PATJ MDM2	3.13e-04	196	38	4	3623_DN
Drug	alpha-estradiol; Up 200; 0.01uM; HL60; HT_HG-U133A	ARHGAP1 ZER1 VPS13B OPCML	3.13e-04	196	38	4	6169_UP
Drug	Riboflavine [83-88-5]; Down 200; 10.6uM; PC3; HT_HG-U133A	CCNT2 ZER1 FAT4 MDM2	3.19e-04	197	38	4	4485_DN
Drug	Piracetam [7491-74-9]; Up 200; 28.2uM; PC3; HT_HG-U133A	COL14A1 GRIN1 OR7A17 MDM2	3.19e-04	197	38	4	5043_UP
Drug	(+,-)-Octopamine hydrochloride [770-05-8]; Up 200; 21uM; HL60; HT_HG-U133A	CNNM4 ZER1 MDM2 VPS13B	3.19e-04	197	38	4	3112_UP
Drug	Doxylamine succinate [562-10-7]; Down 200; 10.2uM; MCF7; HT_HG-U133A	ARHGAP1 CCNT2 NCOR1 MDM2	3.19e-04	197	38	4	1473_DN
Drug	Homatropine hydrobromide (R,S) [51-56-9]; Down 200; 11.2uM; MCF7; HT_HG-U133A	ARHGAP1 CNNM4 PATJ MDM2	3.19e-04	197	38	4	5477_DN
Drug	genistein; Down 200; 10uM; MCF7; HT_HG-U133A_EA	CCNT2 DUSP10 PATJ ADGRL2	3.19e-04	197	38	4	1015_DN
Drug	Vinpocetine [42971-09-5]; Down 200; 11.4uM; MCF7; HT_HG-U133A	ARHGAP1 ZER1 MDM2 VPS13B	3.19e-04	197	38	4	3174_DN
Drug	Phentolamine hydrochloride [73-05-2]; Down 200; 12.6uM; PC3; HT_HG-U133A	CCNT2 ZER1 PATJ AP3B1	3.19e-04	197	38	4	4336_DN
Drug	Cefepime hydrochloride [123171-59-5]; Up 200; 7.4uM; PC3; HT_HG-U133A	SLC17A4 COL14A1 FAT4 OPCML	3.19e-04	197	38	4	5761_UP
Drug	Eucatropine hydrochloride [536-93-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	CCNT2 PATJ MDM2 VPS13B	3.19e-04	197	38	4	3935_DN
Drug	Dioxybenzone [131-53-3]; Down 200; 16.4uM; PC3; HT_HG-U133A	CCNT2 COL14A1 AP3B1 OPCML	3.19e-04	197	38	4	4638_DN
Drug	U-62066 [87151-85-7]; Up 200; 1uM; PC3; HT_HG-U133A	ZER1 COL14A1 PBRM1 OPCML	3.19e-04	197	38	4	3818_UP
Drug	Cefotetan [69712-56-7]; Down 200; 7uM; MCF7; HT_HG-U133A	CCNT2 PATJ MDM2 AP3B1	3.25e-04	198	38	4	4116_DN
Drug	Etodolac [41340-25-4]; Up 200; 14uM; MCF7; HT_HG-U133A	ZER1 COL14A1 DUSP10 PATJ	3.25e-04	198	38	4	7006_UP
Drug	Glafenine hydrochloride [65513-72-6]; Up 200; 9.8uM; MCF7; HT_HG-U133A	CCNT2 ZER1 PATJ MDM2	3.25e-04	198	38	4	7018_UP
Drug	Clebopride maleate [84370-95-6]; Down 200; 8.2uM; MCF7; HT_HG-U133A	ARHGAP1 CCNT2 ZER1 PATJ	3.25e-04	198	38	4	5412_DN
Drug	Neostigmine bromide [114-80-7]; Up 200; 13.2uM; HL60; HT_HG-U133A	SLC17A4 ARHGAP1 COL14A1 OR7A17	3.25e-04	198	38	4	2432_UP
Drug	0173570-0000 [211245-44-2]; Up 200; 1uM; PC3; HT_HG-U133A	CCNT2 ZER1 PATJ MDM2	3.25e-04	198	38	4	7391_UP
Drug	Sulfisoxazole [127-69-5]; Up 200; 15uM; MCF7; HT_HG-U133A	ZER1 COL14A1 FAT4 MDM2	3.25e-04	198	38	4	5257_UP
Drug	Oleandomycin phosphate [7060-74-4]; Up 200; 5uM; MCF7; HT_HG-U133A	ZER1 DUSP10 PATJ OPCML	3.25e-04	198	38	4	1518_UP
Drug	Methantheline bromide [53-46-3]; Up 200; 9.6uM; MCF7; HT_HG-U133A	SLC17A4 DEPDC5 PATJ MDM2	3.25e-04	198	38	4	6254_UP
Drug	(S)-(-)-Cycloserine [339-72-0]; Down 200; 39.2uM; MCF7; HT_HG-U133A	ZER1 DUSP10 MDM2 VPS13B	3.31e-04	199	38	4	4346_DN
Drug	haloperidol; Down 200; 10uM; MCF7; HT_HG-U133A	CNNM4 OGT PATJ AP3B1	3.31e-04	199	38	4	6923_DN
Drug	L(-)-vesamicol hydrochloride [112709-59-8]; Up 200; 13.6uM; HL60; HT_HG-U133A	CNNM4 ZER1 COL14A1 MDM2	3.31e-04	199	38	4	3118_UP
Drug	Naphazoline hydrochloride [550-99-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A	ARHGAP1 CCNT2 PATJ MDM2	3.31e-04	199	38	4	1466_DN
Drug	Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; MCF7; HT_HG-U133A	CCNT2 ZER1 MDM2 CARMIL1	3.31e-04	199	38	4	5006_DN
Drug	Mefenamic acid [61-68-7]; Down 200; 16.6uM; MCF7; HT_HG-U133A	NCOR1 OGT AKAP9 AP3B1	3.31e-04	199	38	4	5534_DN
Drug	Aztreonam [78110-38-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	CNNM4 OGT AKAP9 MDM2	3.31e-04	199	38	4	5535_DN
Drug	Sulpiride [15676-16-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A	ZER1 XK MDM2 AP3B1	3.31e-04	199	38	4	1467_DN
Drug	Metoclopramide monohydrochloride [7232-21-5]; Up 200; 11.8uM; MCF7; HT_HG-U133A	DEPDC5 MDM2 VPS13B OPCML	3.31e-04	199	38	4	2315_UP
Drug	Picotamide monohydrate [80530-63-8]; Down 200; 10.2uM; PC3; HT_HG-U133A	NCOR1 XK AKAP9 AP3B1	3.31e-04	199	38	4	7140_DN
Drug	Urapidil hydrochloride [64887-14-5]; Down 200; 9.4uM; MCF7; HT_HG-U133A	CNNM4 PATJ MDM2 AP3B1	3.31e-04	199	38	4	5295_DN
Drug	Moxonidine [75438-57-2]; Up 200; 16.6uM; HL60; HT_HG-U133A	GRIN1 MDM2 ADGRL2 OPCML	3.31e-04	199	38	4	2923_UP
Drug	Zomepirac sodium salt [64092-48-4]; Up 200; 12.8uM; HL60; HT_HG-U133A	SLC17A4 CNNM4 GRIN1 MDM2	3.38e-04	200	38	4	2713_UP
Drug	Prilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; MCF7; HT_HG-U133A	SLC17A4 ZER1 OGT MDM2	3.38e-04	200	38	4	2314_UP
Drug	Bupropion hydrochloride [31677-93-7]; Down 200; 14.4uM; PC3; HT_HG-U133A	FAT4 XK MDM2 AP3B1	3.38e-04	200	38	4	5782_DN
Drug	Canavanine sulfate monohydrate (L,+) [206996-57-8]; Up 200; 13.6uM; HL60; HT_HG-U133A	SLC17A4 ADGRL2 VPS13B CARMIL1	3.38e-04	200	38	4	2141_UP
Disease	leptin measurement	PATJ LEP OPCML	1.57e-04	81	38	3	EFO_0005000
Disease	pancreatic ductal carcinoma (is_implicated_in)	HEATR1 MDM2	1.92e-04	16	38	2	DOID:3587 (is_implicated_in)
Disease	amino acid measurement	CCNT2 COL14A1 FAT4 ADGRL2 CARMIL1 CBLN2	2.12e-04	678	38	6	EFO_0005134
Disease	Psychotic Disorders	GRIN1 PBRM1 LEP	3.01e-04	101	38	3	C0033975
Disease	Malignant neoplasm of breast	CNNM4 NCOR1 PBRM1 AKAP9 MDM2 LEP VPS13B	3.90e-04	1074	38	7	C0006142
Disease	autism spectrum disorder symptom	PATJ CBLN1	4.02e-04	23	38	2	EFO_0005426
Disease	Cleft palate, cleft lip	PKHD1 DEPDC5 ABCA13 VPS13B	4.48e-04	279	38	4	EFO_0003959, HP_0000175
Disease	Endogenous Hyperinsulinism	CD68 LEP	5.15e-04	26	38	2	C1257963
Disease	Exogenous Hyperinsulinism	CD68 LEP	5.15e-04	26	38	2	C1257964
Disease	Compensatory Hyperinsulinemia	CD68 LEP	5.15e-04	26	38	2	C1257965
Disease	Hyperinsulinism	CD68 LEP	5.98e-04	28	38	2	C0020459
Disease	waist-hip ratio	SLC17A4 COL14A1 PBRM1 IQCH PATJ AP3B1 OPCML	8.56e-04	1226	38	7	EFO_0004343
Disease	pancreatitis (biomarker_via_orthology)	DUSP10 MDM2	1.16e-03	39	38	2	DOID:4989 (biomarker_via_orthology)
Disease	Neoplasm of uncertain or unknown behavior of breast	NCOR1 PBRM1	1.28e-03	41	38	2	C0496956
Disease	Breast adenocarcinoma	NCOR1 PBRM1	1.28e-03	41	38	2	C0858252
Disease	DNA methylation	PKHD1 FAT4 ADGRL2 AP3B1 ABCA13	1.46e-03	656	38	5	GO_0006306
Disease	grey matter volume measurement	XK ADGRL2	1.48e-03	44	38	2	EFO_0005420
Disease	obsolete aging, epigenetic status	PKHD1 CARMIL1	1.61e-03	46	38	2	EFO_0000473, GO_0007568
Disease	memory performance	XK HEATR1 PBRM1 NT5DC2	1.85e-03	409	38	4	EFO_0004874

Protein segments in the cluster

Peptide	Gene	Start	Entry
YGQQIVQMKQELIRQ	AKAP9	441	Q99996
LNVSQLTINTAIVYM	CCNT2	51	O60583
INGQLSYTIIQQMPR	FAT4	1451	Q6V0I7
DTLYSIMQQSVQNLV	ABCA13	2556	Q86UQ4
IYATEQNNGMIVISQ	ADGRL2	276	O95490
NREVQYIVLQNIATM	AP3B1	346	O00203
YSQQQMIEQLSQLIT	IQCH	631	Q86VS3
HLQAQIQIRVMYTTQ	CD68	171	P34810
RLMQGYQIIVQPKTQ	DEPDC5	806	O75140
YQQIKMPISLQQIRT	PBRM1	421	Q86U86
DTMQRLNIGYVINVT	DUSP10	341	Q9Y6W6
VYQQILTSMPSRNVI	LEP	81	P41159
LVNTPTQYSIMIQNV	OPCML	91	Q14982
VYNRQTIQVSLMLNG	CBLN1	121	P23435
IQGLMPDQNYTVQII	COL14A1	86	Q05707
QTIQVSLMQNGYPVI	CBLN2	156	Q8IUK8
YRLQQGIVTSTTQQM	CARMIL1	676	Q5VZK9
MIVYVGNLNLVAVNT	DDX53	426	Q86TM3
VQHQIQSLMNILQYL	HEATR1	1456	Q9H583
IVQGIAQVMVLTGQY	SLC17A4	171	Q9Y2C5
IQQRNGVIITTYQML	ERCC6L	191	Q2NKX8
ISQPLRYVTIMNTQL	OR4D1	126	Q15615
VIEMINRGQIQITIN	OGT	786	O15294
IMSELISNGIQIYQL	SEPTIN14	211	Q6ZU15
QTILNDYITSQQMQV	NCOR1	1611	O75376
GTLYQRMVIAEQNLT	PIK3R6	131	Q5UE93
TMIYRNLVVVNQQES	MDM2	101	Q00987
NTQVVREVQQKYNMG	ARHGAP1	286	Q07960
EVMLQQTQVATVINY	MUTYH	131	Q9UIF7
MLINIQTQSRVITYA	OR7A17	81	O14581
QAYTVTNNLVVLMTQ	PKHD1	3056	P08F94
ITRQQYQNGLLASRM	CNNM4	711	Q6P4Q7
RQVIQVVLNGMESYQ	ZER1	436	Q7Z7L7
SVIQQMAQGRQIEYI	PATJ	121	Q8NI35
QQALTGLLERMQTYQ	NT5DC2	401	Q9H857
CISSMVQQGIQIIQI	VPS13B	3091	Q7Z7G8
QLTLQLYISVMQQDV	XK	151	P51811
YSIMNLQNRKLVQVG	GRIN1	351	Q05586